533 related articles for article (PubMed ID: 10379467)
1. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
Bjarnason I
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S27-36. PubMed ID: 10379467
[TBL] [Abstract][Full Text] [Related]
2. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
3. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
Dammann HG
Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
5. Detection and prevention of NSAID-induced enteropathy.
Davies NM; Saleh JY; Skjodt NM
J Pharm Pharm Sci; 2000; 3(1):137-55. PubMed ID: 10954683
[TBL] [Abstract][Full Text] [Related]
6. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology].
Ledro Cano D; Gómez Rodríguez BJ; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban JM; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 1999 Apr; 91(4):305-9. PubMed ID: 10348929
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors. What is their place?
McGettigan P
Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
[TBL] [Abstract][Full Text] [Related]
8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
9. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
[TBL] [Abstract][Full Text] [Related]
10. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
11. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
12. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
He W; Liu CF; Huang CQ
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825
[TBL] [Abstract][Full Text] [Related]
13. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E
Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602
[No Abstract] [Full Text] [Related]
14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
15. [Selective COX-2 non-steroidal anti-inflammatory agents and gastrointestinal toxicity].
Zaragoza A; Llorente MJ; García MM; Ramírez JJ; Lloret G; Machancoses A
Rev Esp Enferm Dig; 2001 Dec; 93(12):819-20. PubMed ID: 11995364
[No Abstract] [Full Text] [Related]
16. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
17. What are the risks of long-term NSAIDs and COX-2 inhibitors?
DeBisschop M
J Fam Pract; 2003 Mar; 52(3):199-200. PubMed ID: 12620173
[TBL] [Abstract][Full Text] [Related]
18. COX-2 inhibitors.
Brooks PM; Day RO
Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
[TBL] [Abstract][Full Text] [Related]
19. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
20. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]